메뉴 건너뛰기




Volumn 36, Issue 1, 2016, Pages 69-86

Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease

Author keywords

bile acids; farnesoid X receptor; fatty acids; FGF15 19; peroxisomal proliferator activated receptor; RAR related orphan receptor gamma two; TGR5; Vitamin D; xenobiotic sensors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; GLITAZONE DERIVATIVE; HORMONE RECEPTOR STIMULATING AGENT; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PREGNANE X RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR GAMMA; VITAMIN D RECEPTOR; ANTIINFLAMMATORY AGENT; CELL RECEPTOR;

EID: 84958206076     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0036-1571296     Document Type: Article
Times cited : (92)

References (248)
  • 1
    • 77949875356 scopus 로고    scopus 로고
    • Nuclear receptors, inflammation, and liver disease: Insights for cholestatic and fatty liver diseases
    • Arrese M., Karpen S. J. Nuclear receptors, inflammation, and liver disease: Insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther: 2010; 87 4 473 478
    • (2010) Clin Pharmacol Ther , vol.87 , Issue.4 , pp. 473-478
    • Arrese, M.1    Karpen, S.J.2
  • 2
    • 0023857147 scopus 로고
    • Identification of a new class of steroid hormone receptors
    • Giguère V., Yang N., Segui P., Evans R. M. Identification of a new class of steroid hormone receptors. Nature: 1988; 331 6151 91 94
    • (1988) Nature , vol.331 , Issue.6151 , pp. 91-94
    • Giguère, V.1    Yang, N.2    Segui, P.3    Evans, R.M.4
  • 3
    • 65549145901 scopus 로고    scopus 로고
    • Nuclear receptors as therapeutic targets in cholestatic liver diseases
    • Zollner G., Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol: 2009; 156 1 7 27
    • (2009) Br J Pharmacol , vol.156 , Issue.1 , pp. 7-27
    • Zollner, G.1    Trauner, M.2
  • 4
    • 84887599824 scopus 로고    scopus 로고
    • Bile acid-mediated control of liver triglycerides
    • Fuchs C., Claudel T., Trauner M. Bile acid-mediated control of liver triglycerides. Semin Liver Dis: 2013; 33 4 330 342
    • (2013) Semin Liver Dis , vol.33 , Issue.4 , pp. 330-342
    • Fuchs, C.1    Claudel, T.2    Trauner, M.3
  • 5
    • 37349114118 scopus 로고    scopus 로고
    • Nuclear receptors: Decoding metabolic disease
    • Sonoda J., Pei L., Evans R. M. Nuclear receptors: Decoding metabolic disease. FEBS Lett: 2008; 582 1 2 9
    • (2008) FEBS Lett , vol.582 , Issue.1 , pp. 2-9
    • Sonoda, J.1    Pei, L.2    Evans, R.M.3
  • 6
    • 79952227694 scopus 로고    scopus 로고
    • Nuclear receptors in liver disease
    • Wagner M., Zollner G., Trauner M. Nuclear receptors in liver disease. Hepatology: 2011; 53 3 1023 1034
    • (2011) Hepatology , vol.53 , Issue.3 , pp. 1023-1034
    • Wagner, M.1    Zollner, G.2    Trauner, M.3
  • 7
    • 8844262660 scopus 로고    scopus 로고
    • Principles for modulation of the nuclear receptor superfamily
    • Gronemeyer H., Gustafsson J. A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov: 2004; 3 11 950 964
    • (2004) Nat Rev Drug Discov , vol.3 , Issue.11 , pp. 950-964
    • Gronemeyer, H.1    Gustafsson, J.A.2    Laudet, V.3
  • 8
    • 0032532721 scopus 로고    scopus 로고
    • Orphan nuclear receptors-new ligands and new possibilities
    • Blumberg B., Evans R. M. Orphan nuclear receptors -new ligands and new possibilities. Genes Dev: 1998; 12 20 3149 3155
    • (1998) Genes Dev , vol.12 , Issue.20 , pp. 3149-3155
    • Blumberg, B.1    Evans, R.M.2
  • 9
    • 36849084107 scopus 로고    scopus 로고
    • Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta
    • Raghuram S., Stayrook K. R., Huang P., et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol: 2007; 14 12 1207 1213
    • (2007) Nat Struct Mol Biol , vol.14 , Issue.12 , pp. 1207-1213
    • Raghuram, S.1    Stayrook, K.R.2    Huang, P.3
  • 10
    • 84922901154 scopus 로고    scopus 로고
    • Identification of natural RORγ ligands that regulate the development of lymphoid cells
    • Santori F. R., Huang P., van de Pavert S. A., et al. Identification of natural RORγ ligands that regulate the development of lymphoid cells. Cell Metab: 2015; 21 2 286 297
    • (2015) Cell Metab , vol.21 , Issue.2 , pp. 286-297
    • Santori, F.R.1    Huang, P.2    Van De Pavert, S.A.3
  • 11
    • 0037129380 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease
    • Angulo P. Nonalcoholic fatty liver disease. N Engl J Med: 2002; 346 16 1221 1231
    • (2002) N Engl J Med , vol.346 , Issue.16 , pp. 1221-1231
    • Angulo, P.1
  • 12
    • 0027447461 scopus 로고
    • Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers
    • Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A: 1993; 90 6 2160 2164
    • (1993) Proc Natl Acad Sci U S A , vol.90 , Issue.6 , pp. 2160-2164
    • Keller, H.1    Dreyer, C.2    Medin, J.3    Mahfoudi, A.4    Ozato, K.5    Wahli, W.6
  • 13
    • 0033998334 scopus 로고    scopus 로고
    • The PPARs: From orphan receptors to drug discovery
    • Willson T. M., Brown P. J., Sternbach D. D., Henke B. R. The PPARs: From orphan receptors to drug discovery. J Med Chem: 2000; 43 4 527 550
    • (2000) J Med Chem , vol.43 , Issue.4 , pp. 527-550
    • Willson, T.M.1    Brown, P.J.2    Sternbach, D.D.3    Henke, B.R.4
  • 14
    • 0034669025 scopus 로고    scopus 로고
    • Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta
    • Repa J. J., Liang G., Ou J., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev: 2000; 14 22 2819 2830
    • (2000) Genes Dev , vol.14 , Issue.22 , pp. 2819-2830
    • Repa, J.J.1    Liang, G.2    Ou, J.3
  • 15
    • 0013199471 scopus 로고    scopus 로고
    • Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha
    • Peet D. J., Turley S. D., Ma W., et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell: 1998; 93 5 693 704
    • (1998) Cell , vol.93 , Issue.5 , pp. 693-704
    • Peet, D.J.1    Turley, S.D.2    Ma, W.3
  • 16
    • 0033591297 scopus 로고    scopus 로고
    • Identification of a nuclear receptor for bile acids
    • Makishima M., Okamoto A. Y., Repa J. J., et al. Identification of a nuclear receptor for bile acids. Science: 1999; 284 5418 1362 1365
    • (1999) Science , vol.284 , Issue.5418 , pp. 1362-1365
    • Makishima, M.1    Okamoto, A.Y.2    Repa, J.J.3
  • 17
    • 0033591387 scopus 로고    scopus 로고
    • Bile acids: Natural ligands for an orphan nuclear receptor
    • Parks D. J., Blanchard S. G., Bledsoe R. K., et al. Bile acids: Natural ligands for an orphan nuclear receptor. Science: 1999; 284 5418 1365 1368
    • (1999) Science , vol.284 , Issue.5418 , pp. 1365-1368
    • Parks, D.J.1    Blanchard, S.G.2    Bledsoe, R.K.3
  • 18
    • 0033026760 scopus 로고    scopus 로고
    • Endogenous bile acids are ligands for the nuclear receptor FXR/BAR
    • Wang H., Chen J., Hollister K., Sowers L. C., Forman B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell: 1999; 3 5 543 553
    • (1999) Mol Cell , vol.3 , Issue.5 , pp. 543-553
    • Wang, H.1    Chen, J.2    Hollister, K.3    Sowers, L.C.4    Forman, B.M.5
  • 19
    • 84880664792 scopus 로고    scopus 로고
    • Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
    • Mudaliar S., Henry R. R., Sanyal A. J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology: 2013; 145 3 574 82.e1
    • (2013) Gastroenterology , vol.145 , Issue.3 , pp. 574-82e1
    • Mudaliar, S.1    Henry, R.R.2    Sanyal, A.J.3
  • 20
    • 65749115425 scopus 로고    scopus 로고
    • Non alcoholic fatty liver disease and metabolic syndrome
    • Paschos P., Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia: 2009; 13 1 9 19
    • (2009) Hippokratia , vol.13 , Issue.1 , pp. 9-19
    • Paschos, P.1    Paletas, K.2
  • 21
    • 84859157277 scopus 로고    scopus 로고
    • Roles of PPARs in NAFLD: Potential therapeutic targets
    • Tailleux A., Wouters K., Staels B. Roles of PPARs in NAFLD: Potential therapeutic targets. Biochim Biophys Acta: 2012; 1821 5 809 818
    • (2012) Biochim Biophys Acta , vol.1821 , Issue.5 , pp. 809-818
    • Tailleux, A.1    Wouters, K.2    Staels, B.3
  • 22
    • 33644652183 scopus 로고    scopus 로고
    • Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
    • Lefebvre P., Chinetti G., Fruchart J. C., Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest: 2006; 116 3 571 580
    • (2006) J Clin Invest , vol.116 , Issue.3 , pp. 571-580
    • Lefebvre, P.1    Chinetti, G.2    Fruchart, J.C.3    Staels, B.4
  • 23
    • 50649089597 scopus 로고    scopus 로고
    • Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
    • Staels B., Maes M., Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med: 2008; 5 9 542 553
    • (2008) Nat Clin Pract Cardiovasc Med , vol.5 , Issue.9 , pp. 542-553
    • Staels, B.1    Maes, M.2    Zambon, A.3
  • 24
    • 0035024343 scopus 로고    scopus 로고
    • A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle
    • Minnich A., Tian N., Byan L., Bilder G. A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab: 2001; 280 2 E270 E279
    • (2001) Am J Physiol Endocrinol Metab , vol.280 , Issue.2 , pp. E270-E279
    • Minnich, A.1    Tian, N.2    Byan, L.3    Bilder, G.4
  • 25
    • 0028817459 scopus 로고
    • Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
    • Staels B., Vu-Dac N., Kosykh V. A., et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest: 1995; 95 2 705 712
    • (1995) J Clin Invest , vol.95 , Issue.2 , pp. 705-712
    • Staels, B.1    Vu-Dac, N.2    Kosykh, V.A.3
  • 26
    • 0037438377 scopus 로고    scopus 로고
    • Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation
    • Kleemann R., Gervois P. P., Verschuren L., Staels B., Princen H. M., Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood: 2003; 101 2 545 551
    • (2003) Blood , vol.101 , Issue.2 , pp. 545-551
    • Kleemann, R.1    Gervois, P.P.2    Verschuren, L.3    Staels, B.4    Princen, H.M.5    Kooistra, T.6
  • 27
    • 0032565868 scopus 로고    scopus 로고
    • Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
    • Staels B., Koenig W., Habib A., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature: 1998; 393 6687 790 793
    • (1998) Nature , vol.393 , Issue.6687 , pp. 790-793
    • Staels, B.1    Koenig, W.2    Habib, A.3
  • 28
    • 70350133800 scopus 로고    scopus 로고
    • Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease
    • Belvisi M. G., Mitchell J. A. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol: 2009; 158 4 994 1003
    • (2009) Br J Pharmacol , vol.158 , Issue.4 , pp. 994-1003
    • Belvisi, M.G.1    Mitchell, J.A.2
  • 29
    • 0034666132 scopus 로고    scopus 로고
    • Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting
    • Hashimoto T., Cook W. S., Qi C., Yeldandi A. V., Reddy J. K., Rao M. S. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem: 2000; 275 37 28918 28928
    • (2000) J Biol Chem , vol.275 , Issue.37 , pp. 28918-28928
    • Hashimoto, T.1    Cook, W.S.2    Qi, C.3    Yeldandi, A.V.4    Reddy, J.K.5    Rao, M.S.6
  • 30
    • 0033516569 scopus 로고    scopus 로고
    • Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype
    • Hashimoto T., Fujita T., Usuda N., et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem: 1999; 274 27 19228 19236
    • (1999) J Biol Chem , vol.274 , Issue.27 , pp. 19228-19236
    • Hashimoto, T.1    Fujita, T.2    Usuda, N.3
  • 31
    • 0141446024 scopus 로고    scopus 로고
    • Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
    • Gavrilova O., Haluzik M., Matsusue K., et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem: 2003; 278 36 34268 34276
    • (2003) J Biol Chem , vol.278 , Issue.36 , pp. 34268-34276
    • Gavrilova, O.1    Haluzik, M.2    Matsusue, K.3
  • 32
    • 0037373008 scopus 로고    scopus 로고
    • Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
    • Matsusue K., Haluzik M., Lambert G., et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest: 2003; 111 5 737 747
    • (2003) J Clin Invest , vol.111 , Issue.5 , pp. 737-747
    • Matsusue, K.1    Haluzik, M.2    Lambert, G.3
  • 33
    • 77951457202 scopus 로고    scopus 로고
    • Fibrates, glitazones, and peroxisome proliferator-activated receptors
    • Lalloyer F., Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol: 2010; 30 5 894 899
    • (2010) Arterioscler Thromb Vasc Biol , vol.30 , Issue.5 , pp. 894-899
    • Lalloyer, F.1    Staels, B.2
  • 34
    • 67649090459 scopus 로고    scopus 로고
    • Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease
    • Fiévet C., Staels B. Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. Curr Atheroscler Rep: 2009; 11 4 281 288
    • (2009) Curr Atheroscler Rep , vol.11 , Issue.4 , pp. 281-288
    • Fiévet, C.1    Staels, B.2
  • 35
    • 49649129066 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice
    • Qin X., Xie X., Fan Y., et al. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology: 2008; 48 2 432 441
    • (2008) Hepatology , vol.48 , Issue.2 , pp. 432-441
    • Qin, X.1    Xie, X.2    Fan, Y.3
  • 36
    • 0038643427 scopus 로고    scopus 로고
    • Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice
    • Ip E., Farrell G. C., Robertson G., Hall P., Kirsch R., Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology: 2003; 38 1 123 132
    • (2003) Hepatology , vol.38 , Issue.1 , pp. 123-132
    • Ip, E.1    Farrell, G.C.2    Robertson, G.3    Hall, P.4    Kirsch, R.5    Leclercq, I.6
  • 37
    • 34250821923 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation
    • Stienstra R., Mandard S., Patsouris D., Maass C., Kersten S., Müller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology: 2007; 148 6 2753 2763
    • (2007) Endocrinology , vol.148 , Issue.6 , pp. 2753-2763
    • Stienstra, R.1    Mandard, S.2    Patsouris, D.3    Maass, C.4    Kersten, S.5    Müller, M.6
  • 38
    • 79959696573 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice
    • Lalloyer F., Wouters K., Baron M., et al. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol: 2011; 31 7 1573 1579
    • (2011) Arterioscler Thromb Vasc Biol , vol.31 , Issue.7 , pp. 1573-1579
    • Lalloyer, F.1    Wouters, K.2    Baron, M.3
  • 39
    • 33644919989 scopus 로고    scopus 로고
    • Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates
    • Shiri-Sverdlov R., Wouters K., van Gorp P. J., et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol: 2006; 44 4 732 741
    • (2006) J Hepatol , vol.44 , Issue.4 , pp. 732-741
    • Shiri-Sverdlov, R.1    Wouters, K.2    Van Gorp, P.J.3
  • 40
    • 2342644813 scopus 로고    scopus 로고
    • Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice
    • Ip E., Farrell G., Hall P., Robertson G., Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology: 2004; 39 5 1286 1296
    • (2004) Hepatology , vol.39 , Issue.5 , pp. 1286-1296
    • Ip, E.1    Farrell, G.2    Hall, P.3    Robertson, G.4    Leclercq, I.5
  • 41
    • 2542465868 scopus 로고    scopus 로고
    • Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro
    • Kleemann R., Verschuren L., de Rooij B. J., et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood: 2004; 103 11 4188 4194
    • (2004) Blood , vol.103 , Issue.11 , pp. 4188-4194
    • Kleemann, R.1    Verschuren, L.2    De Rooij, B.J.3
  • 42
    • 47949094965 scopus 로고    scopus 로고
    • Integration of metabolism and inflammation by lipid-activated nuclear receptors
    • Bensinger S. J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature: 2008; 454 7203 470 477
    • (2008) Nature , vol.454 , Issue.7203 , pp. 470-477
    • Bensinger, S.J.1    Tontonoz, P.2
  • 43
    • 84931577111 scopus 로고    scopus 로고
    • PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
    • Francque S., Verrijken A., Caron S., et al. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol: 2015; 63 1 164 173
    • (2015) J Hepatol , vol.63 , Issue.1 , pp. 164-173
    • Francque, S.1    Verrijken, A.2    Caron, S.3
  • 44
    • 84929728792 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
    • Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol: 2015; 7 8 1012 1019
    • (2015) World J Hepatol , vol.7 , Issue.8 , pp. 1012-1019
    • Souza-Mello, V.1
  • 45
    • 0344874601 scopus 로고    scopus 로고
    • Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives
    • Chapman M. J. Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis: 2003; 171 1 1 13
    • (2003) Atherosclerosis , vol.171 , Issue.1 , pp. 1-13
    • Chapman, M.J.1
  • 46
    • 84866146620 scopus 로고    scopus 로고
    • Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline
    • Endocrine society
    • Berglund L., Brunzell J. D., Goldberg A. C., et al. Endocrine society. Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab: 2012; 97 9 2969 2989
    • (2012) J Clin Endocrinol Metab , vol.97 , Issue.9 , pp. 2969-2989
    • Berglund, L.1    Brunzell, J.D.2    Goldberg, A.C.3
  • 47
    • 28044452217 scopus 로고    scopus 로고
    • Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
    • FIELD study investigators.
    • Keech A., Simes R. J., Barter P., et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet: 2005; 366 9500 1849 1861
    • (2005) Lancet , vol.366 , Issue.9500 , pp. 1849-1861
    • Keech, A.1    Simes, R.J.2    Barter, P.3
  • 48
    • 50549084740 scopus 로고    scopus 로고
    • Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
    • Ong J. P., Pitts A., Younossi Z. M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol: 2008; 49 4 608 612
    • (2008) J Hepatol , vol.49 , Issue.4 , pp. 608-612
    • Ong, J.P.1    Pitts, A.2    Younossi, Z.M.3
  • 49
    • 84928209634 scopus 로고    scopus 로고
    • Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
    • Ekstedt M., Hagström H., Nasr P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology: 2015; 61 5 1547 1554
    • (2015) Hepatology , vol.61 , Issue.5 , pp. 1547-1554
    • Ekstedt, M.1    Hagström, H.2    Nasr, P.3
  • 50
    • 84885769159 scopus 로고    scopus 로고
    • Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
    • Kostapanos M. S., Kei A., Elisaf M. S. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol: 2013; 5 9 470 478
    • (2013) World J Hepatol , vol.5 , Issue.9 , pp. 470-478
    • Kostapanos, M.S.1    Kei, A.2    Elisaf, M.S.3
  • 51
    • 33745046866 scopus 로고    scopus 로고
    • Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study
    • Athyros V. G., Mikhailidis D. P., Didangelos T. P., et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study. Curr Med Res Opin: 2006; 22 5 873 883
    • (2006) Curr Med Res Opin , vol.22 , Issue.5 , pp. 873-883
    • Athyros, V.G.1    Mikhailidis, D.P.2    Didangelos, T.P.3
  • 52
    • 34447114640 scopus 로고    scopus 로고
    • Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
    • Bajaj M., Suraamornkul S., Hardies L. J., Glass L., Musi N., DeFronzo R. A. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia: 2007; 50 8 1723 1731
    • (2007) Diabetologia , vol.50 , Issue.8 , pp. 1723-1731
    • Bajaj, M.1    Suraamornkul, S.2    Hardies, L.J.3    Glass, L.4    Musi, N.5    DeFronzo, R.A.6
  • 54
    • 84933047295 scopus 로고    scopus 로고
    • Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
    • Laurin J., Lindor K. D., Crippin J. S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology: 1996; 23 6 1464 1467
    • (1996) Hepatology , vol.23 , Issue.6 , pp. 1464-1467
    • Laurin, J.1    Lindor, K.D.2    Crippin, J.S.3
  • 55
    • 84858703583 scopus 로고    scopus 로고
    • Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
    • Parker H. M., Johnson N. A., Burdon C. A., Cohn J. S., O'Connor H. T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol: 2012; 56 4 944 951
    • (2012) J Hepatol , vol.56 , Issue.4 , pp. 944-951
    • Parker, H.M.1    Johnson, N.A.2    Burdon, C.A.3    Cohn, J.S.4    O'Connor, H.T.5    George, J.6
  • 56
    • 79451476075 scopus 로고    scopus 로고
    • The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease
    • Shapiro H., Tehilla M., Attal-Singer J., Bruck R., Luzzatti R., Singer P. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr: 2011; 30 1 6 19
    • (2011) Clin Nutr , vol.30 , Issue.1 , pp. 6-19
    • Shapiro, H.1    Tehilla, M.2    Attal-Singer, J.3    Bruck, R.4    Luzzatti, R.5    Singer, P.6
  • 57
    • 84930268665 scopus 로고    scopus 로고
    • Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
    • Nogueira M. A., Oliveira C. P., Ferreira Alves V. A., et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clin Nutr: 2015
    • (2015) Clin Nutr
    • Nogueira, M.A.1    Oliveira, C.P.2    Ferreira Alves, V.A.3
  • 58
    • 84878349086 scopus 로고    scopus 로고
    • Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
    • Fruchart J. C. Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol: 2013; 12 82
    • (2013) Cardiovasc Diabetol , vol.12 , pp. 82
    • Fruchart, J.C.1
  • 59
    • 84885405205 scopus 로고    scopus 로고
    • Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects
    • Cariou B., Hanf R., Lambert-Porcheron S., et al. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care: 2013; 36 10 2923 2930
    • (2013) Diabetes Care , vol.36 , Issue.10 , pp. 2923-2930
    • Cariou, B.1    Hanf, R.2    Lambert-Porcheron, S.3
  • 60
    • 84888285959 scopus 로고    scopus 로고
    • Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    • Staels B., Rubenstrunk A., Noel B., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology: 2013; 58 6 1941 1952
    • (2013) Hepatology , vol.58 , Issue.6 , pp. 1941-1952
    • Staels, B.1    Rubenstrunk, A.2    Noel, B.3
  • 61
    • 84968850631 scopus 로고    scopus 로고
    • An international, phase 2 randomized controlled trial of the dual PPAR α-δ agonist GFT505 in adult patients with NASH
    • Ratziu V., Bedossa P., et al. An international, phase 2 randomized controlled trial of the dual PPAR α-δ agonist GFT505 in adult patients with NASH. Hepatology: 2015; 62 (S1): 262A
    • (2015) Hepatology , vol.62 , pp. 262A
    • Ratziu, V.1    Bedossa, P.2
  • 62
    • 79751491258 scopus 로고    scopus 로고
    • Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice
    • Nan Y. M., Han F., Kong L. B., et al. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand J Gastroenterol: 2011; 46 3 358 369
    • (2011) Scand J Gastroenterol , vol.46 , Issue.3 , pp. 358-369
    • Nan, Y.M.1    Han, F.2    Kong, L.B.3
  • 63
    • 0036381998 scopus 로고    scopus 로고
    • Adipose tissue as a buffer for daily lipid flux
    • Frayn K. N. Adipose tissue as a buffer for daily lipid flux. Diabetologia: 2002; 45 9 1201 1210
    • (2002) Diabetologia , vol.45 , Issue.9 , pp. 1201-1210
    • Frayn, K.N.1
  • 64
    • 0035462629 scopus 로고    scopus 로고
    • PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
    • Maeda N., Takahashi M., Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes: 2001; 50 9 2094 2099
    • (2001) Diabetes , vol.50 , Issue.9 , pp. 2094-2099
    • Maeda, N.1    Takahashi, M.2    Funahashi, T.3
  • 65
    • 17944365228 scopus 로고    scopus 로고
    • The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
    • Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med: 2001; 7 8 941 946
    • (2001) Nat Med , vol.7 , Issue.8 , pp. 941-946
    • Yamauchi, T.1    Kamon, J.2    Waki, H.3
  • 66
    • 0037494960 scopus 로고    scopus 로고
    • Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
    • Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature: 2003; 423 6941 762 769
    • (2003) Nature , vol.423 , Issue.6941 , pp. 762-769
    • Yamauchi, T.1    Kamon, J.2    Ito, Y.3
  • 67
    • 0033962940 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells
    • Galli A., Crabb D., Price D., et al. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology: 2000; 31 1 101 108
    • (2000) Hepatology , vol.31 , Issue.1 , pp. 101-108
    • Galli, A.1    Crabb, D.2    Price, D.3
  • 68
    • 0034680787 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors and hepatic stellate cell activation
    • Miyahara T., Schrum L., Rippe R., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem: 2000; 275 46 35715 35722
    • (2000) J Biol Chem , vol.275 , Issue.46 , pp. 35715-35722
    • Miyahara, T.1    Schrum, L.2    Rippe, R.3
  • 69
    • 0033855572 scopus 로고    scopus 로고
    • Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells
    • Marra F., Efsen E., Romanelli R. G., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology: 2000; 119 2 466 478
    • (2000) Gastroenterology , vol.119 , Issue.2 , pp. 466-478
    • Marra, F.1    Efsen, E.2    Romanelli, R.G.3
  • 70
    • 33749341729 scopus 로고    scopus 로고
    • PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells
    • Zhao C., Chen W., Yang L., Chen L., Stimpson S. A., Diehl A. M. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun: 2006; 350 2 385 391
    • (2006) Biochem Biophys Res Commun , vol.350 , Issue.2 , pp. 385-391
    • Zhao, C.1    Chen, W.2    Yang, L.3    Chen, L.4    Stimpson, S.A.5    Diehl, A.M.6
  • 71
    • 14244257340 scopus 로고    scopus 로고
    • Adipogenic transcriptional regulation of hepatic stellate cells
    • She H., Xiong S., Hazra S., Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem: 2005; 280 6 4959 4967
    • (2005) J Biol Chem , vol.280 , Issue.6 , pp. 4959-4967
    • She, H.1    Xiong, S.2    Hazra, S.3    Tsukamoto, H.4
  • 72
    • 60349100000 scopus 로고    scopus 로고
    • Over-expression of C/EBP-alpha induces apoptosis in cultured rat hepatic stellate cells depending on p53 and peroxisome proliferator-activated receptor-gamma
    • Wang X., Huang G., Mei S., Qian J., Ji J., Zhang J. Over-expression of C/EBP-alpha induces apoptosis in cultured rat hepatic stellate cells depending on p53 and peroxisome proliferator-activated receptor-gamma. Biochem Biophys Res Commun: 2009; 380 2 286 291
    • (2009) Biochem Biophys Res Commun , vol.380 , Issue.2 , pp. 286-291
    • Wang, X.1    Huang, G.2    Mei, S.3    Qian, J.4    Ji, J.5    Zhang, J.6
  • 73
    • 0142093152 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors: New targets for the pharmacological modulation of macrophage gene expression and function
    • Chinetti G., Fruchart J. C., Staels B. Peroxisome proliferator-activated receptors: New targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol: 2003; 14 5 459 468
    • (2003) Curr Opin Lipidol , vol.14 , Issue.5 , pp. 459-468
    • Chinetti, G.1    Fruchart, J.C.2    Staels, B.3
  • 74
    • 34547492488 scopus 로고    scopus 로고
    • PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
    • Bouhlel M. A., Derudas B., Rigamonti E., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab: 2007; 6 2 137 143
    • (2007) Cell Metab , vol.6 , Issue.2 , pp. 137-143
    • Bouhlel, M.A.1    Derudas, B.2    Rigamonti, E.3
  • 75
    • 77957919796 scopus 로고    scopus 로고
    • PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice
    • Foryst-Ludwig A., Hartge M., Clemenz M., et al. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol: 2010; 9 64
    • (2010) Cardiovasc Diabetol , vol.9 , pp. 64
    • Foryst-Ludwig, A.1    Hartge, M.2    Clemenz, M.3
  • 76
    • 84939938313 scopus 로고    scopus 로고
    • Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    • Watanabe S., Hashimoto E., Ikejima K., et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol: 2015; 50 4 364 377
    • (2015) J Gastroenterol , vol.50 , Issue.4 , pp. 364-377
    • Watanabe, S.1    Hashimoto, E.2    Ikejima, K.3
  • 77
    • 84861543083 scopus 로고    scopus 로고
    • The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
    • Chalasani N., Younossi Z., Lavine J. E., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology: 2012; 55 6 2005 2023
    • (2012) Hepatology , vol.55 , Issue.6 , pp. 2005-2023
    • Chalasani, N.1    Younossi, Z.2    Lavine, J.E.3
  • 78
    • 33751545838 scopus 로고    scopus 로고
    • A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    • Belfort R., Harrison S. A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med: 2006; 355 22 2297 2307
    • (2006) N Engl J Med , vol.355 , Issue.22 , pp. 2297-2307
    • Belfort, R.1    Harrison, S.A.2    Brown, K.3
  • 79
    • 46349088361 scopus 로고    scopus 로고
    • Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial
    • LIDO Study Group
    • Ratziu V., Giral P., Jacqueminet S., et al. LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology: 2008; 135 1 100 110
    • (2008) Gastroenterology , vol.135 , Issue.1 , pp. 100-110
    • Ratziu, V.1    Giral, P.2    Jacqueminet, S.3
  • 80
    • 9644266912 scopus 로고    scopus 로고
    • Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial
    • Smith S. R., De Jonge L., Volaufova J., Li Y., Xie H., Bray G. A. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism: 2005; 54 1 24 32
    • (2005) Metabolism , vol.54 , Issue.1 , pp. 24-32
    • Smith, S.R.1    De Jonge, L.2    Volaufova, J.3    Li, Y.4    Xie, H.5    Bray, G.A.6
  • 81
    • 75449116707 scopus 로고    scopus 로고
    • Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
    • LIDO Study Group
    • Ratziu V., Charlotte F., Bernhardt C., et al. LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology: 2010; 51 2 445 453
    • (2010) Hepatology , vol.51 , Issue.2 , pp. 445-453
    • Ratziu, V.1    Charlotte, F.2    Bernhardt, C.3
  • 82
    • 77951874018 scopus 로고    scopus 로고
    • Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis
    • NASH CRN
    • Sanyal A. J., Chalasani N., Kowdley K. V., et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
    • (2010) N Engl J Med , vol.362 , Issue.18 , pp. 1675-1685
    • Sanyal, A.J.1    Chalasani, N.2    Kowdley, K.V.3
  • 83
    • 14944359845 scopus 로고    scopus 로고
    • A pilot study of Vitamin E versus Vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis
    • Sanyal A. J., Mofrad P. S., Contos M. J., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol: 2004; 2 12 1107 1115
    • (2004) Clin Gastroenterol Hepatol , vol.2 , Issue.12 , pp. 1107-1115
    • Sanyal, A.J.1    Mofrad, P.S.2    Contos, M.J.3
  • 84
    • 0141532275 scopus 로고    scopus 로고
    • Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone
    • Neuschwander-Tetri B. A., Brunt E. M., Wehmeier K. R., Oliver D., Bacon B. R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology: 2003; 38 4 1008 1017
    • (2003) Hepatology , vol.38 , Issue.4 , pp. 1008-1017
    • Neuschwander-Tetri, B.A.1    Brunt, E.M.2    Wehmeier, K.R.3    Oliver, D.4    Bacon, B.R.5
  • 86
    • 78649596998 scopus 로고    scopus 로고
    • Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues
    • Ratziu V., Caldwell S., Neuschwander-Tetri B. A. Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. Hepatology: 2010; 52 6 2206 2215
    • (2010) Hepatology , vol.52 , Issue.6 , pp. 2206-2215
    • Ratziu, V.1    Caldwell, S.2    Neuschwander-Tetri, B.A.3
  • 87
    • 84900822867 scopus 로고    scopus 로고
    • Extended treatment with pioglitazone improves liver histology in patients with prediabetes or type 2 diabetes mellitus and NASH
    • Cusi K., Orsak B., Lomonaco R., et al. Extended treatment with pioglitazone improves liver histology in patients with prediabetes or type 2 diabetes mellitus and NASH. Hepatology: 2013; 58 (S1): 248A
    • (2013) Hepatology , vol.58 , pp. 248A
    • Cusi, K.1    Orsak, B.2    Lomonaco, R.3
  • 88
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen S. E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med: 2007; 356 24 2457 2471
    • (2007) N Engl J Med , vol.356 , Issue.24 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 89
    • 84880919064 scopus 로고    scopus 로고
    • Results of a reevaluation of cardiovascular outcomes in the RECORD trial
    • Mahaffey K. W., Hafley G., Dickerson S., et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J: 2013; 166 2 240 249.e1
    • (2013) Am Heart J , vol.166 , Issue.2 , pp. 240-249e1
    • Mahaffey, K.W.1    Hafley, G.2    Dickerson, S.3
  • 90
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial
    • PROactive investigators
    • Dormandy J. A., Charbonnel B., Eckland D. J., et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet: 2005; 366 9493 1279 1289
    • (2005) Lancet , vol.366 , Issue.9493 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3
  • 92
    • 84902603532 scopus 로고    scopus 로고
    • Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis
    • Turner R. M., Kwok C. S., Chen-Turner C., Maduakor C. A., Singh S., Loke Y. K. Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis. Br J Clin Pharmacol: 2014; 78 2 258 273
    • (2014) Br J Clin Pharmacol , vol.78 , Issue.2 , pp. 258-273
    • Turner, R.M.1    Kwok, C.S.2    Chen-Turner, C.3    Maduakor, C.A.4    Singh, S.5    Loke, Y.K.6
  • 93
    • 84924662049 scopus 로고    scopus 로고
    • Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis
    • Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium.
    • Levin D., Bell S., Sund R., et al. Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium. Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis. Diabetologia: 2015; 58 3 493 504
    • (2015) Diabetologia , vol.58 , Issue.3 , pp. 493-504
    • Levin, D.1    Bell, S.2    Sund, R.3
  • 94
    • 84908381489 scopus 로고    scopus 로고
    • L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation
    • Xie X., Zhou X., Chen W., et al. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation. Biochim Biophys Acta: 2015; 1850 1 62 72
    • (2015) Biochim Biophys Acta , vol.1850 , Issue.1 , pp. 62-72
    • Xie, X.1    Zhou, X.2    Chen, W.3
  • 95
    • 84903550477 scopus 로고    scopus 로고
    • Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?
    • INT131-007 Study Group
    • DePaoli A. M., Higgins L. S., Henry R. R., Mantzoros C., Dunn F. L.; INT131-007 Study Group. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care: 2014; 37 7 1918 1923
    • (2014) Diabetes Care , vol.37 , Issue.7 , pp. 1918-1923
    • DePaoli, A.M.1    Higgins, L.S.2    Henry, R.R.3    Mantzoros, C.4    Dunn, F.L.5
  • 96
    • 84878911175 scopus 로고    scopus 로고
    • Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis
    • quiz 892
    • Singh S., Singh P. P., Singh A. G., Murad M. H., Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. Am J Gastroenterol: 2013; 108 6 881 891, quiz 892
    • (2013) Am J Gastroenterol , vol.108 , Issue.6 , pp. 881-891
    • Singh, S.1    Singh, P.P.2    Singh, A.G.3    Murad, M.H.4    Sanchez, W.5
  • 97
    • 84874660234 scopus 로고    scopus 로고
    • Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: Population-based and in vitro studies
    • Chen H-P, Shieh J. J., Chang C. C., et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: Population-based and in vitro studies. Gut: 2013; 62 4 606 615
    • (2013) Gut , vol.62 , Issue.4 , pp. 606-615
    • Chen, H.-P.1    Shieh, J.J.2    Chang, C.C.3
  • 98
    • 33645891166 scopus 로고    scopus 로고
    • Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- And choline-deficient diet
    • Nagasawa T., Inada Y., Nakano S., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- And choline-deficient diet. Eur J Pharmacol: 2006; 536 1-2 182 191
    • (2006) Eur J Pharmacol , vol.536 , Issue.1-2 , pp. 182-191
    • Nagasawa, T.1    Inada, Y.2    Nakano, S.3
  • 99
    • 0038153044 scopus 로고    scopus 로고
    • Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells
    • Hoekstra M., Kruijt J. K., Van Eck M., Van Berkel T. J. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J Biol Chem: 2003; 278 28 25448 25453
    • (2003) J Biol Chem , vol.278 , Issue.28 , pp. 25448-25453
    • Hoekstra, M.1    Kruijt, J.K.2    Van Eck, M.3    Van Berkel, T.J.4
  • 100
    • 44349112305 scopus 로고    scopus 로고
    • Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity
    • Kang K., Reilly S. M., Karabacak V., et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab: 2008; 7 6 485 495
    • (2008) Cell Metab , vol.7 , Issue.6 , pp. 485-495
    • Kang, K.1    Reilly, S.M.2    Karabacak, V.3
  • 101
    • 44349161098 scopus 로고    scopus 로고
    • Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance
    • Odegaard J. I., Ricardo-Gonzalez R. R., Red Eagle A., et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab: 2008; 7 6 496 507
    • (2008) Cell Metab , vol.7 , Issue.6 , pp. 496-507
    • Odegaard, J.I.1    Ricardo-Gonzalez, R.R.2    Red Eagle, A.3
  • 102
    • 33846443997 scopus 로고    scopus 로고
    • Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist
    • Sprecher D. L., Massien C., Pearce G., et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol: 2007; 27 2 359 365
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , Issue.2 , pp. 359-365
    • Sprecher, D.L.1    Massien, C.2    Pearce, G.3
  • 103
    • 39649101196 scopus 로고    scopus 로고
    • Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men
    • Risérus U., Sprecher D., Johnson T., et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes: 2008; 57 2 332 339
    • (2008) Diabetes , vol.57 , Issue.2 , pp. 332-339
    • Risérus, U.1    Sprecher, D.2    Johnson, T.3
  • 104
    • 84865507796 scopus 로고    scopus 로고
    • Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: Characteristics of metabolic syndrome
    • Olson E. J., Pearce G. L., Jones N. P., Sprecher D. L. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol: 2012; 32 9 2289 2294
    • (2012) Arterioscler Thromb Vasc Biol , vol.32 , Issue.9 , pp. 2289-2294
    • Olson, E.J.1    Pearce, G.L.2    Jones, N.P.3    Sprecher, D.L.4
  • 105
    • 80052539818 scopus 로고    scopus 로고
    • MBX-8025, a novel peroxisome proliferator receptor-delta agonist: Lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin
    • Bays H. E., Schwartz S., Littlejohn T. III., et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab: 2011; 96 9 2889 2897
    • (2011) J Clin Endocrinol Metab , vol.96 , Issue.9 , pp. 2889-2897
    • Bays, H.E.1    Schwartz, S.2    Littlejohn, T.3
  • 106
    • 84885400267 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor delta and cardiovascular disease
    • Ehrenborg E., Skogsberg J. Peroxisome proliferator-activated receptor delta and cardiovascular disease. Atherosclerosis: 2013; 231 1 95 106
    • (2013) Atherosclerosis , vol.231 , Issue.1 , pp. 95-106
    • Ehrenborg, E.1    Skogsberg, J.2
  • 107
    • 84893649359 scopus 로고    scopus 로고
    • New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease
    • Sahebkar A., Chew G. T., Watts G. F. New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother: 2014; 15 4 493 503
    • (2014) Expert Opin Pharmacother , vol.15 , Issue.4 , pp. 493-503
    • Sahebkar, A.1    Chew, G.T.2    Watts, G.F.3
  • 108
    • 84861437351 scopus 로고    scopus 로고
    • Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
    • Iwaisako K., Haimerl M., Paik Y. H., et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A: 2012; 109 21 E1369 E1376
    • (2012) Proc Natl Acad Sci U S A , vol.109 , Issue.21 , pp. E1369-E1376
    • Iwaisako, K.1    Haimerl, M.2    Paik, Y.H.3
  • 109
    • 58249110568 scopus 로고    scopus 로고
    • Role of bile acids and bile acid receptors in metabolic regulation
    • Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev: 2009; 89 1 147 191
    • (2009) Physiol Rev , vol.89 , Issue.1 , pp. 147-191
    • Lefebvre, P.1    Cariou, B.2    Lien, F.3    Kuipers, F.4    Staels, B.5
  • 110
    • 84865499656 scopus 로고    scopus 로고
    • Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
    • Adorini L., Pruzanski M., Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today: 2012; 17 17-18 988 997
    • (2012) Drug Discov Today , vol.17 , Issue.17-18 , pp. 988-997
    • Adorini, L.1    Pruzanski, M.2    Shapiro, D.3
  • 112
    • 84910031461 scopus 로고    scopus 로고
    • Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer
    • Tsuei J., Chau T., Mills D., Wan Y. J. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med (Maywood): 2014; 239 11 1489 1504
    • (2014) Exp Biol Med (Maywood) , vol.239 , Issue.11 , pp. 1489-1504
    • Tsuei, J.1    Chau, T.2    Mills, D.3    Wan, Y.J.4
  • 114
    • 37349010675 scopus 로고    scopus 로고
    • FXR signaling in metabolic disease
    • Zhang Y., Edwards P. A. FXR signaling in metabolic disease. FEBS Lett: 2008; 582 1 10 18
    • (2008) FEBS Lett , vol.582 , Issue.1 , pp. 10-18
    • Zhang, Y.1    Edwards, P.A.2
  • 115
    • 77249108800 scopus 로고    scopus 로고
    • Bile acid sequestrants for lipid and glucose control
    • Staels B., Handelsman Y., Fonseca V. Bile acid sequestrants for lipid and glucose control. Curr Diab Rep: 2010; 10 1 70 77
    • (2010) Curr Diab Rep , vol.10 , Issue.1 , pp. 70-77
    • Staels, B.1    Handelsman, Y.2    Fonseca, V.3
  • 116
    • 33645509321 scopus 로고    scopus 로고
    • Farnesoid X receptor is essential for normal glucose homeostasis
    • Ma K., Saha P. K., Chan L., Moore D. D. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest: 2006; 116 4 1102 1109
    • (2006) J Clin Invest , vol.116 , Issue.4 , pp. 1102-1109
    • Ma, K.1    Saha, P.K.2    Chan, L.3    Moore, D.D.4
  • 117
    • 70349430938 scopus 로고    scopus 로고
    • Bile acids: Regulation of synthesis
    • Chiang J. Y. Bile acids: Regulation of synthesis. J Lipid Res: 2009; 50 10 1955 1966
    • (2009) J Lipid Res , vol.50 , Issue.10 , pp. 1955-1966
    • Chiang, J.Y.1
  • 118
    • 84870334072 scopus 로고    scopus 로고
    • Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo
    • Kir S., Zhang Y., Gerard R. D., Kliewer S. A., Mangelsdorf D. J. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem: 2012; 287 49 41334 41341
    • (2012) J Biol Chem , vol.287 , Issue.49 , pp. 41334-41341
    • Kir, S.1    Zhang, Y.2    Gerard, R.D.3    Kliewer, S.A.4    Mangelsdorf, D.J.5
  • 119
    • 84870556105 scopus 로고    scopus 로고
    • Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver
    • Cicione C., Degirolamo C., Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology: 2012; 56 6 2404 2411
    • (2012) Hepatology , vol.56 , Issue.6 , pp. 2404-2411
    • Cicione, C.1    Degirolamo, C.2    Moschetta, A.3
  • 120
    • 84946088116 scopus 로고    scopus 로고
    • Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
    • Trabelsi M. S., Daoudi M., Prawitt J., et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun: 2015; 6 7629
    • (2015) Nat Commun , vol.6 , pp. 7629
    • Trabelsi, M.S.1    Daoudi, M.2    Prawitt, J.3
  • 121
    • 84895520482 scopus 로고    scopus 로고
    • The bile acid TGR5 membrane receptor: From basic research to clinical application
    • Duboc H., Taché Y., Hofmann A. F. The bile acid TGR5 membrane receptor: From basic research to clinical application. Dig Liver Dis: 2014; 46 4 302 312
    • (2014) Dig Liver Dis , vol.46 , Issue.4 , pp. 302-312
    • Duboc, H.1    Taché, Y.2    Hofmann, A.F.3
  • 122
    • 31444454037 scopus 로고    scopus 로고
    • Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
    • Watanabe M., Houten S. M., Mataki C., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature: 2006; 439 7075 484 489
    • (2006) Nature , vol.439 , Issue.7075 , pp. 484-489
    • Watanabe, M.1    Houten, S.M.2    Mataki, C.3
  • 123
    • 79955890870 scopus 로고    scopus 로고
    • Bile acid metabolism and the pathogenesis of type 2 diabetes
    • Prawitt J., Caron S., Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep: 2011; 11 3 160 166
    • (2011) Curr Diab Rep , vol.11 , Issue.3 , pp. 160-166
    • Prawitt, J.1    Caron, S.2    Staels, B.3
  • 124
    • 0034664729 scopus 로고    scopus 로고
    • Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
    • Sinal C. J., Tohkin M., Miyata M., Ward J. M., Lambert G., Gonzalez F. J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell: 2000; 102 6 731 744
    • (2000) Cell , vol.102 , Issue.6 , pp. 731-744
    • Sinal, C.J.1    Tohkin, M.2    Miyata, M.3    Ward, J.M.4    Lambert, G.5    Gonzalez, F.J.6
  • 125
    • 33847044019 scopus 로고    scopus 로고
    • Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor
    • Yang F., Huang X., Yi T., Yen Y., Moore D. D., Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res: 2007; 67 3 863 867
    • (2007) Cancer Res , vol.67 , Issue.3 , pp. 863-867
    • Yang, F.1    Huang, X.2    Yi, T.3    Yen, Y.4    Moore, D.D.5    Huang, W.6
  • 126
    • 84946605496 scopus 로고    scopus 로고
    • FXR induces SOCS3 and suppresses hepatocellular carcinoma
    • Guo F., Xu Z., Zhang Y., et al. FXR induces SOCS3 and suppresses hepatocellular carcinoma. Oncotarget: 2015; 6 33 34606 34616
    • (2015) Oncotarget , vol.6 , Issue.33 , pp. 34606-34616
    • Guo, F.1    Xu, Z.2    Zhang, Y.3
  • 127
    • 84924231007 scopus 로고    scopus 로고
    • Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
    • Liu X., Zhang X., Ji L., Gu J., Zhou M., Chen S. Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma. Oncotarget: 2015; 6 6 4226 4238
    • (2015) Oncotarget , vol.6 , Issue.6 , pp. 4226-4238
    • Liu, X.1    Zhang, X.2    Ji, L.3    Gu, J.4    Zhou, M.5    Chen, S.6
  • 128
    • 84920964414 scopus 로고    scopus 로고
    • Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation
    • Degirolamo C., Modica S., Vacca M., et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology: 2015; 61 1 161 170
    • (2015) Hepatology , vol.61 , Issue.1 , pp. 161-170
    • Degirolamo, C.1    Modica, S.2    Vacca, M.3
  • 129
    • 84924301185 scopus 로고    scopus 로고
    • Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development
    • Uriarte I., Latasa M. U., Carotti S., et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer: 2015; 136 10 2469 2475
    • (2015) Int J Cancer , vol.136 , Issue.10 , pp. 2469-2475
    • Uriarte, I.1    Latasa, M.U.2    Carotti, S.3
  • 130
    • 84920971419 scopus 로고    scopus 로고
    • Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma
    • Gauglhofer C., Paur J., Schrottmaier W. C., et al. Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma. Carcinogenesis: 2014; 35 10 2331 2338
    • (2014) Carcinogenesis , vol.35 , Issue.10 , pp. 2331-2338
    • Gauglhofer, C.1    Paur, J.2    Schrottmaier, W.C.3
  • 131
    • 84887686733 scopus 로고    scopus 로고
    • FGFR4 and TGF-β1 expression in hepatocellular carcinoma: Correlation with clinicopathological features and prognosis
    • Chen Z., Xie B., Zhu Q., et al. FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis. Int J Med Sci: 2013; 10 13 1868 1875
    • (2013) Int J Med Sci , vol.10 , Issue.13 , pp. 1868-1875
    • Chen, Z.1    Xie, B.2    Zhu, Q.3
  • 132
    • 85047694456 scopus 로고    scopus 로고
    • Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
    • Watanabe M., Houten S. M., Wang L., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest: 2004; 113 10 1408 1418
    • (2004) J Clin Invest , vol.113 , Issue.10 , pp. 1408-1418
    • Watanabe, M.1    Houten, S.M.2    Wang, L.3
  • 133
    • 13844280404 scopus 로고    scopus 로고
    • Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor
    • Savkur R. S., Bramlett K. S., Michael L. F., Burris T. P. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. Biochem Biophys Res Commun: 2005; 329 1 391 396
    • (2005) Biochem Biophys Res Commun , vol.329 , Issue.1 , pp. 391-396
    • Savkur, R.S.1    Bramlett, K.S.2    Michael, L.F.3    Burris, T.P.4
  • 134
    • 67649210759 scopus 로고    scopus 로고
    • Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
    • Zhang S., Wang J., Liu Q., Harnish D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol: 2009; 51 2 380 388
    • (2009) J Hepatol , vol.51 , Issue.2 , pp. 380-388
    • Zhang, S.1    Wang, J.2    Liu, Q.3    Harnish, D.C.4
  • 135
    • 0037101810 scopus 로고    scopus 로고
    • 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
    • Pellicciari R., Fiorucci S., Camaioni E., et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem: 2002; 45 17 3569 3572
    • (2002) J Med Chem , vol.45 , Issue.17 , pp. 3569-3572
    • Pellicciari, R.1    Fiorucci, S.2    Camaioni, E.3
  • 137
    • 78650769613 scopus 로고    scopus 로고
    • Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes
    • Vignozzi L., Morelli A., Filippi S., et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med: 2011; 8 1 57 77
    • (2011) J Sex Med , vol.8 , Issue.1 , pp. 57-77
    • Vignozzi, L.1    Morelli, A.2    Filippi, S.3
  • 138
    • 71449109826 scopus 로고    scopus 로고
    • The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria
    • Wang X. X., Jiang T., Shen Y., et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol: 2009; 297 6 F1587 F1596
    • (2009) Am J Physiol Renal Physiol , vol.297 , Issue.6 , pp. F1587-F1596
    • Wang, X.X.1    Jiang, T.2    Shen, Y.3
  • 139
    • 78049299629 scopus 로고    scopus 로고
    • Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model
    • Wang X. X., Jiang T., Shen Y., et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes: 2010; 59 11 2916 2927
    • (2010) Diabetes , vol.59 , Issue.11 , pp. 2916-2927
    • Wang, X.X.1    Jiang, T.2    Shen, Y.3
  • 140
    • 84929266699 scopus 로고    scopus 로고
    • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial
    • NASH Clinical Research Network
    • Neuschwander-Tetri B. A., Loomba R., Sanyal A. J., et al. NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet: 2015; 385 9972 956 965
    • (2015) Lancet , vol.385 , Issue.9972 , pp. 956-965
    • Neuschwander-Tetri, B.A.1    Loomba, R.2    Sanyal, A.J.3
  • 141
    • 77950613528 scopus 로고    scopus 로고
    • FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
    • Cipriani S., Mencarelli A., Palladino G., Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res: 2010; 51 4 771 784
    • (2010) J Lipid Res , vol.51 , Issue.4 , pp. 771-784
    • Cipriani, S.1    Mencarelli, A.2    Palladino, G.3    Fiorucci, S.4
  • 142
    • 84925226080 scopus 로고    scopus 로고
    • The immunomodulatory role of bile acids
    • Sipka S., Bruckner G. The immunomodulatory role of bile acids. Int Arch Allergy Immunol: 2014; 165 1 1 8
    • (2014) Int Arch Allergy Immunol , vol.165 , Issue.1 , pp. 1-8
    • Sipka, S.1    Bruckner, G.2
  • 143
    • 56149126257 scopus 로고    scopus 로고
    • Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: New insights into hepatic inflammation
    • Wagner M., Zollner G., Trauner M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: New insights into hepatic inflammation. Hepatology: 2008; 48 5 1383 1386
    • (2008) Hepatology , vol.48 , Issue.5 , pp. 1383-1386
    • Wagner, M.1    Zollner, G.2    Trauner, M.3
  • 144
    • 77149159568 scopus 로고    scopus 로고
    • The bile acid receptor FXR is a modulator of intestinal innate immunity
    • Vavassori P., Mencarelli A., Renga B., Distrutti E., Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol: 2009; 183 10 6251 6261
    • (2009) J Immunol , vol.183 , Issue.10 , pp. 6251-6261
    • Vavassori, P.1    Mencarelli, A.2    Renga, B.3    Distrutti, E.4    Fiorucci, S.5
  • 145
    • 79952535597 scopus 로고    scopus 로고
    • Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
    • Gadaleta R. M., van Erpecum K. J., Oldenburg B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut: 2011; 60 4 463 472
    • (2011) Gut , vol.60 , Issue.4 , pp. 463-472
    • Gadaleta, R.M.1    Van Erpecum, K.J.2    Oldenburg, B.3
  • 147
    • 67650566600 scopus 로고    scopus 로고
    • Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- And apoE-/- mice
    • Hartman H. B., Gardell S. J., Petucci C. J., Wang S., Krueger J. A., Evans M. J. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- And apoE-/- mice. J Lipid Res: 2009; 50 6 1090 1100
    • (2009) J Lipid Res , vol.50 , Issue.6 , pp. 1090-1100
    • Hartman, H.B.1    Gardell, S.J.2    Petucci, C.J.3    Wang, S.4    Krueger, J.A.5    Evans, M.J.6
  • 148
    • 84869205703 scopus 로고    scopus 로고
    • Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice
    • Hambruch E., Miyazaki-Anzai S., Hahn U., et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther: 2012; 343 3 556 567
    • (2012) J Pharmacol Exp Ther , vol.343 , Issue.3 , pp. 556-567
    • Hambruch, E.1    Miyazaki-Anzai, S.2    Hahn, U.3
  • 149
    • 36349013143 scopus 로고    scopus 로고
    • Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration
    • Li Y. T., Swales K. E., Thomas G. J., Warner T. D., Bishop-Bailey D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol: 2007; 27 12 2606 2611
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , Issue.12 , pp. 2606-2611
    • Li, Y.T.1    Swales, K.E.2    Thomas, G.J.3    Warner, T.D.4    Bishop-Bailey, D.5
  • 150
    • 0033172845 scopus 로고    scopus 로고
    • Review article: Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases
    • Trauner M., Graziadei I. W. Review article: Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther: 1999; 13 8 979 996
    • (1999) Aliment Pharmacol Ther , vol.13 , Issue.8 , pp. 979-996
    • Trauner, M.1    Graziadei, I.W.2
  • 151
    • 84862144999 scopus 로고    scopus 로고
    • Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice
    • Tsuchida T., Shiraishi M., Ohta T., Sakai K., Ishii S. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism: 2012; 61 7 944 953
    • (2012) Metabolism , vol.61 , Issue.7 , pp. 944-953
    • Tsuchida, T.1    Shiraishi, M.2    Ohta, T.3    Sakai, K.4    Ishii, S.5
  • 152
    • 33748069813 scopus 로고    scopus 로고
    • Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes
    • Ozcan U., Yilmaz E., Ozcan L., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science: 2006; 313 5790 1137 1140
    • (2006) Science , vol.313 , Issue.5790 , pp. 1137-1140
    • Ozcan, U.1    Yilmaz, E.2    Ozcan, L.3
  • 153
    • 84904012910 scopus 로고    scopus 로고
    • Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice
    • Legry V., Van Rooyen D. M., Lambert B., et al. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice. Clin Sci (Lond): 2014; 127 7 507 518
    • (2014) Clin Sci (Lond) , vol.127 , Issue.7 , pp. 507-518
    • Legry, V.1    Van Rooyen, D.M.2    Lambert, B.3
  • 154
    • 83755181906 scopus 로고    scopus 로고
    • Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury
    • Moustafa T., Fickert P., Magnes C., et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology: 2012; 142 1 140 151.e12
    • (2012) Gastroenterology , vol.142 , Issue.1 , pp. 140-151e12
    • Moustafa, T.1    Fickert, P.2    Magnes, C.3
  • 155
    • 77952561299 scopus 로고    scopus 로고
    • Bile acids as regulators of hepatic lipid and glucose metabolism
    • Trauner M., Claudel T., Fickert P., Moustafa T., Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis: 2010; 28 1 220 224
    • (2010) Dig Dis , vol.28 , Issue.1 , pp. 220-224
    • Trauner, M.1    Claudel, T.2    Fickert, P.3    Moustafa, T.4    Wagner, M.5
  • 156
    • 79851511413 scopus 로고    scopus 로고
    • Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis
    • Beraza N., Ofner-Ziegenfuss L., Ehedego H., et al. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut: 2011; 60 3 387 396
    • (2011) Gut , vol.60 , Issue.3 , pp. 387-396
    • Beraza, N.1    Ofner-Ziegenfuss, L.2    Ehedego, H.3
  • 157
    • 84920401295 scopus 로고    scopus 로고
    • Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
    • Jiang C., Xie C., Li F., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest: 2015; 125 1 386 402
    • (2015) J Clin Invest , vol.125 , Issue.1 , pp. 386-402
    • Jiang, C.1    Xie, C.2    Li, F.3
  • 158
    • 84887960056 scopus 로고    scopus 로고
    • Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity
    • Li F., Jiang C., Krausz K. W., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun: 2013; 4 2384
    • (2013) Nat Commun , vol.4 , pp. 2384
    • Li, F.1    Jiang, C.2    Krausz, K.W.3
  • 159
    • 78049522194 scopus 로고    scopus 로고
    • Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
    • Tilg H., Moschen A. R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology: 2010; 52 5 1836 1846
    • (2010) Hepatology , vol.52 , Issue.5 , pp. 1836-1846
    • Tilg, H.1    Moschen, A.R.2
  • 160
    • 84880664792 scopus 로고    scopus 로고
    • Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
    • Mudaliar S., Henry R. R., Sanyal A. J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology: 2013; 145 3 574 82.e1
    • (2013) Gastroenterology , vol.145 , Issue.3 , pp. 574-82e1
    • Mudaliar, S.1    Henry, R.R.2    Sanyal, A.J.3
  • 161
    • 33645738747 scopus 로고    scopus 로고
    • Endocrine functions of bile acids
    • Houten S. M., Watanabe M., Auwerx J. Endocrine functions of bile acids. EMBO J: 2006; 25 7 1419 1425
    • (2006) EMBO J , vol.25 , Issue.7 , pp. 1419-1425
    • Houten, S.M.1    Watanabe, M.2    Auwerx, J.3
  • 162
    • 0036218724 scopus 로고    scopus 로고
    • Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element
    • Claudel T., Sturm E., Duez H., et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest: 2002; 109 7 961 971
    • (2002) J Clin Invest , vol.109 , Issue.7 , pp. 961-971
    • Claudel, T.1    Sturm, E.2    Duez, H.3
  • 163
    • 26244441014 scopus 로고    scopus 로고
    • The farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism
    • Claudel T., Staels B., Kuipers F. The farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol: 2005; 25 10 2020 2030
    • (2005) Arterioscler Thromb Vasc Biol , vol.25 , Issue.10 , pp. 2020-2030
    • Claudel, T.1    Staels, B.2    Kuipers, F.3
  • 164
    • 79955442715 scopus 로고    scopus 로고
    • Deciphering the nuclear bile acid receptor FXR paradigm
    • Modica S., Gadaleta R. M., Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal: 2010; 8 e005
    • (2010) Nucl Recept Signal , vol.8 , pp. e005
    • Modica, S.1    Gadaleta, R.M.2    Moschetta, A.3
  • 165
    • 84863427742 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease: The bile acid-activated farnesoid x receptor as an emerging treatment target
    • Fuchs M. Non-alcoholic fatty liver disease: The bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids: 2012; 2012 934396
    • (2012) J Lipids , vol.2012 , pp. 934396
    • Fuchs, M.1
  • 166
    • 77956189968 scopus 로고    scopus 로고
    • The inflamed liver and atherosclerosis: A link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk
    • Alkhouri N., Tamimi T. A., Yerian L., Lopez R., Zein N. N., Feldstein A. E. The inflamed liver and atherosclerosis: A link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci: 2010; 55 9 2644 2650
    • (2010) Dig Dis Sci , vol.55 , Issue.9 , pp. 2644-2650
    • Alkhouri, N.1    Tamimi, T.A.2    Yerian, L.3    Lopez, R.4    Zein, N.N.5    Feldstein, A.E.6
  • 167
    • 34248223285 scopus 로고    scopus 로고
    • Biology of incretins: GLP-1 and GIP
    • Baggio L. L., Drucker D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology: 2007; 132 6 2131 2157
    • (2007) Gastroenterology , vol.132 , Issue.6 , pp. 2131-2157
    • Baggio, L.L.1    Drucker, D.J.2
  • 168
    • 84937053742 scopus 로고    scopus 로고
    • Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
    • TECOS Study Group
    • Green J. B., Bethel M. A., Armstrong P. W., et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med: 2015; 373 3 232 242
    • (2015) N Engl J Med , vol.373 , Issue.3 , pp. 232-242
    • Green, J.B.1    Bethel, M.A.2    Armstrong, P.W.3
  • 169
    • 84976223148 scopus 로고    scopus 로고
    • Incretin-based therapies for the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
    • Carbone L. J., Angus P. W., Yeomans N. D. Incretin-based therapies for the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol: 2015
    • (2015) J Gastroenterol Hepatol
    • Carbone, L.J.1    Angus, P.W.2    Yeomans, N.D.3
  • 170
    • 84958193043 scopus 로고    scopus 로고
    • ClinicalTrials.com. 2015. Available at: Accessed January 3, 2016
    • ClinicalTrials.com. 2015. Obeticholic acid. Available at: https://clinicaltrials.gov/ct2/results?term=fxr+fg. Accessed January 3, 2016
    • Obeticholic acid
  • 171
    • 77249102583 scopus 로고    scopus 로고
    • The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance
    • Schreuder T. C., Marsman H. A., Lenicek M., et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol: 2010; 298 3 G440 G445
    • (2010) Am J Physiol Gastrointest Liver Physiol , vol.298 , Issue.3 , pp. G440-G445
    • Schreuder, T.C.1    Marsman, H.A.2    Lenicek, M.3
  • 172
    • 84879468929 scopus 로고    scopus 로고
    • Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease
    • Alisi A., Ceccarelli S., Panera N., et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS ONE: 2013; 8 6 e67160
    • (2013) PLoS ONE , vol.8 , Issue.6 , pp. e67160
    • Alisi, A.1    Ceccarelli, S.2    Panera, N.3
  • 173
    • 84885382835 scopus 로고    scopus 로고
    • A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass
    • Gerhard G. S., Styer A. M., Wood G. C., et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care: 2013; 36 7 1859 1864
    • (2013) Diabetes Care , vol.36 , Issue.7 , pp. 1859-1864
    • Gerhard, G.S.1    Styer, A.M.2    Wood, G.C.3
  • 174
    • 84876209742 scopus 로고    scopus 로고
    • Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids
    • Kohli R., Bradley D., Setchell K. D., Eagon J. C., Abumrad N., Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab: 2013; 98 4 E708 E712
    • (2013) J Clin Endocrinol Metab , vol.98 , Issue.4 , pp. E708-E712
    • Kohli, R.1    Bradley, D.2    Setchell, K.D.3    Eagon, J.C.4    Abumrad, N.5    Klein, S.6
  • 175
    • 84885298843 scopus 로고    scopus 로고
    • Mechanisms underlying weight loss after bariatric surgery
    • Miras A. D., le Roux C. W. Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol: 2013; 10 10 575 584
    • (2013) Nat Rev Gastroenterol Hepatol , vol.10 , Issue.10 , pp. 575-584
    • Miras, A.D.1    Le Roux, C.W.2
  • 176
    • 84898051705 scopus 로고    scopus 로고
    • FXR is a molecular target for the effects of vertical sleeve gastrectomy
    • Ryan K. K., Tremaroli V., Clemmensen C., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature: 2014; 509 7499 183 188
    • (2014) Nature , vol.509 , Issue.7499 , pp. 183-188
    • Ryan, K.K.1    Tremaroli, V.2    Clemmensen, C.3
  • 177
    • 84898030895 scopus 로고    scopus 로고
    • FXR: The key to benefits in bariatric surgery?
    • Kuipers F., Groen A. K. FXR: The key to benefits in bariatric surgery? Nat Med: 2014; 20 4 337 338
    • (2014) Nat Med , vol.20 , Issue.4 , pp. 337-338
    • Kuipers, F.1    Groen, A.K.2
  • 178
    • 1542515099 scopus 로고    scopus 로고
    • Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
    • Lindor K. D., Kowdley K. V., Heathcote E. J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology: 2004; 39 3 770 778
    • (2004) Hepatology , vol.39 , Issue.3 , pp. 770-778
    • Lindor, K.D.1    Kowdley, K.V.2    Heathcote, E.J.3
  • 179
    • 77955699301 scopus 로고    scopus 로고
    • High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial
    • NASH Study Group
    • Leuschner U. F., Lindenthal B., Herrmann G., et al. NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial. Hepatology: 2010; 52 2 472 479
    • (2010) Hepatology , vol.52 , Issue.2 , pp. 472-479
    • Leuschner, U.F.1    Lindenthal, B.2    Herrmann, G.3
  • 180
    • 79954764140 scopus 로고    scopus 로고
    • A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis
    • FRESGUN
    • Ratziu V., de Ledinghen V., Oberti F., et al. FRESGUN. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol: 2011; 54 5 1011 1019
    • (2011) J Hepatol , vol.54 , Issue.5 , pp. 1011-1019
    • Ratziu, V.1    De Ledinghen, V.2    Oberti, F.3
  • 181
    • 84929607710 scopus 로고    scopus 로고
    • Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
    • Mueller M., Thorell A., Claudel T., et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol: 2015; 62 6 1398 1404
    • (2015) J Hepatol , vol.62 , Issue.6 , pp. 1398-1404
    • Mueller, M.1    Thorell, A.2    Claudel, T.3
  • 182
    • 34248198871 scopus 로고    scopus 로고
    • Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice
    • Flowers J. B., Rabaglia M. E., Schueler K. L., et al. Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice. Diabetes: 2007; 56 5 1228 1239
    • (2007) Diabetes , vol.56 , Issue.5 , pp. 1228-1239
    • Flowers, J.B.1    Rabaglia, M.E.2    Schueler, K.L.3
  • 183
    • 33644821916 scopus 로고    scopus 로고
    • Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans
    • Hulver M. W., Berggren J. R., Carper M. J., et al. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab: 2005; 2 4 251 261
    • (2005) Cell Metab , vol.2 , Issue.4 , pp. 251-261
    • Hulver, M.W.1    Berggren, J.R.2    Carper, M.J.3
  • 184
    • 84918843434 scopus 로고    scopus 로고
    • The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease
    • FLORA Group
    • Safadi R., Konikoff F. M., Mahamid M., et al. FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol: 2014; 12 12 2085 91.e1
    • (2014) Clin Gastroenterol Hepatol , vol.12 , Issue.12 , pp. 2085-91e1
    • Safadi, R.1    Konikoff, F.M.2    Mahamid, M.3
  • 185
    • 2342652187 scopus 로고    scopus 로고
    • Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver
    • Dobrzyn P., Dobrzyn A., Miyazaki M., et al. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc Natl Acad Sci U S A: 2004; 101 17 6409 6414
    • (2004) Proc Natl Acad Sci U S A , vol.101 , Issue.17 , pp. 6409-6414
    • Dobrzyn, P.1    Dobrzyn, A.2    Miyazaki, M.3
  • 186
    • 0342316532 scopus 로고    scopus 로고
    • Oxysterols: Modulators of cholesterol metabolism and other processes
    • Schroepfer Jr. G. J. Oxysterols: Modulators of cholesterol metabolism and other processes. Physiol Rev: 2000; 80 1 361 554
    • (2000) Physiol Rev , vol.80 , Issue.1 , pp. 361-554
    • Schroepfer, G.J.1
  • 187
    • 0037192797 scopus 로고    scopus 로고
    • Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors
    • Joseph S. B., Laffitte B. A., Patel P. H., et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem: 2002; 277 13 11019 11025
    • (2002) J Biol Chem , vol.277 , Issue.13 , pp. 11019-11025
    • Joseph, S.B.1    Laffitte, B.A.2    Patel, P.H.3
  • 188
    • 0036251153 scopus 로고    scopus 로고
    • SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver
    • Horton J. D., Goldstein J. L., Brown M. S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest: 2002; 109 9 1125 1131
    • (2002) J Clin Invest , vol.109 , Issue.9 , pp. 1125-1131
    • Horton, J.D.1    Goldstein, J.L.2    Brown, M.S.3
  • 189
    • 64749108682 scopus 로고    scopus 로고
    • Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia
    • Kratzer A., Buchebner M., Pfeifer T., et al. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res: 2009; 50 2 312 326
    • (2009) J Lipid Res , vol.50 , Issue.2 , pp. 312-326
    • Kratzer, A.1    Buchebner, M.2    Pfeifer, T.3
  • 190
    • 79954596966 scopus 로고    scopus 로고
    • Liver x receptors in atherosclerosis and inflammation
    • Im S. S., Osborne T. F. Liver x receptors in atherosclerosis and inflammation. Circ Res: 2011; 108 8 996 1001
    • (2011) Circ Res , vol.108 , Issue.8 , pp. 996-1001
    • Im, S.S.1    Osborne, T.F.2
  • 191
    • 77956365905 scopus 로고    scopus 로고
    • The liver X receptor: Control of cellular lipid homeostasis and beyond Implications for drug design
    • Oosterveer M. H., Grefhorst A., Groen A. K., Kuipers F. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design. Prog Lipid Res: 2010; 49 4 343 352
    • (2010) Prog Lipid Res , vol.49 , Issue.4 , pp. 343-352
    • Oosterveer, M.H.1    Grefhorst, A.2    Groen, A.K.3    Kuipers, F.4
  • 192
    • 0037072732 scopus 로고    scopus 로고
    • Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles
    • Grefhorst A., Elzinga B. M., Voshol P. J., et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem: 2002; 277 37 34182 34190
    • (2002) J Biol Chem , vol.277 , Issue.37 , pp. 34182-34190
    • Grefhorst, A.1    Elzinga, B.M.2    Voshol, P.J.3
  • 193
    • 33846864235 scopus 로고    scopus 로고
    • Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor alpha
    • van der Veen J. N., Havinga R., Bloks V. W., Groen A. K., Kuipers F. Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor alpha. J Lipid Res: 2007; 48 2 337 347
    • (2007) J Lipid Res , vol.48 , Issue.2 , pp. 337-347
    • Van Der Veen, J.N.1    Havinga, R.2    Bloks, V.W.3    Groen, A.K.4    Kuipers, F.5
  • 194
    • 0038353226 scopus 로고    scopus 로고
    • Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor
    • Inaba T., Matsuda M., Shimamura M., et al. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem: 2003; 278 24 21344 21351
    • (2003) J Biol Chem , vol.278 , Issue.24 , pp. 21344-21351
    • Inaba, T.1    Matsuda, M.2    Shimamura, M.3
  • 195
    • 0037072759 scopus 로고    scopus 로고
    • ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase
    • Shimizugawa T., Ono M., Shimamura M., et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem: 2002; 277 37 33742 33748
    • (2002) J Biol Chem , vol.277 , Issue.37 , pp. 33742-33748
    • Shimizugawa, T.1    Ono, M.2    Shimamura, M.3
  • 196
    • 38649096259 scopus 로고    scopus 로고
    • Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis
    • Zhou J., Febbraio M., Wada T., et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology: 2008; 134 2 556 567
    • (2008) Gastroenterology , vol.134 , Issue.2 , pp. 556-567
    • Zhou, J.1    Febbraio, M.2    Wada, T.3
  • 197
    • 40549125618 scopus 로고    scopus 로고
    • ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver
    • Denechaud P. D., Bossard P., Lobaccaro J. M., et al. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest: 2008; 118 3 956 964
    • (2008) J Clin Invest , vol.118 , Issue.3 , pp. 956-964
    • Denechaud, P.D.1    Bossard, P.2    Lobaccaro, J.M.3
  • 198
    • 84924281209 scopus 로고    scopus 로고
    • The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
    • Griffett K., Welch R. D., Flaveny C. A., Kolar G. R., Neuschwander-Tetri B. A., Burris T. P. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol Metab: 2015; 4 4 353 357
    • (2015) Mol Metab , vol.4 , Issue.4 , pp. 353-357
    • Griffett, K.1    Welch, R.D.2    Flaveny, C.A.3    Kolar, G.R.4    Neuschwander-Tetri, B.A.5    Burris, T.P.6
  • 199
    • 84912525212 scopus 로고    scopus 로고
    • Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease
    • Ahn S. B., Jang K., Jun D. W., Lee B. H., Shin K. J. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci: 2014; 59 12 2975 2982
    • (2014) Dig Dis Sci , vol.59 , Issue.12 , pp. 2975-2982
    • Ahn, S.B.1    Jang, K.2    Jun, D.W.3    Lee, B.H.4    Shin, K.J.5
  • 200
    • 67049144914 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants
    • Katz A., Udata C., Ott E., et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol: 2009; 49 6 643 649
    • (2009) J Clin Pharmacol , vol.49 , Issue.6 , pp. 643-649
    • Katz, A.1    Udata, C.2    Ott, E.3
  • 201
    • 84884300669 scopus 로고    scopus 로고
    • The liver X receptor: A master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease
    • Ducheix S., Montagner A., Theodorou V., Ferrier L., Guillou H. The liver X receptor: A master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease. Biochem Pharmacol: 2013; 86 1 96 105
    • (2013) Biochem Pharmacol , vol.86 , Issue.1 , pp. 96-105
    • Ducheix, S.1    Montagner, A.2    Theodorou, V.3    Ferrier, L.4    Guillou, H.5
  • 202
    • 84897071025 scopus 로고    scopus 로고
    • Vitamin D metabolism, mechanism of action, and clinical applications
    • Bikle D. D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol: 2014; 21 3 319 329
    • (2014) Chem Biol , vol.21 , Issue.3 , pp. 319-329
    • Bikle, D.D.1
  • 203
    • 84883259255 scopus 로고    scopus 로고
    • Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association?
    • Kwok R. M., Torres D. M., Harrison S. A. Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association? Hepatology: 2013; 58 3 1166 1174
    • (2013) Hepatology , vol.58 , Issue.3 , pp. 1166-1174
    • Kwok, R.M.1    Torres, D.M.2    Harrison, S.A.3
  • 205
    • 84867746418 scopus 로고    scopus 로고
    • Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism
    • Yin Y., Yu Z., Xia M., Luo X., Lu X., Ling W. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. Eur J Clin Invest: 2012; 42 11 1189 1196
    • (2012) Eur J Clin Invest , vol.42 , Issue.11 , pp. 1189-1196
    • Yin, Y.1    Yu, Z.2    Xia, M.3    Luo, X.4    Lu, X.5    Ling, W.6
  • 206
    • 84876279910 scopus 로고    scopus 로고
    • The role of Vitamin D receptor in innate and adaptive immunity: A study in hereditary Vitamin D-resistant rickets patients
    • Tiosano D., Wildbaum G., Gepstein V., et al. The role of vitamin D receptor in innate and adaptive immunity: A study in hereditary vitamin D-resistant rickets patients. J Clin Endocrinol Metab: 2013; 98 4 1685 1693
    • (2013) J Clin Endocrinol Metab , vol.98 , Issue.4 , pp. 1685-1693
    • Tiosano, D.1    Wildbaum, G.2    Gepstein, V.3
  • 207
    • 78649816415 scopus 로고    scopus 로고
    • Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression
    • Chang S. H., Chung Y., Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem: 2010; 285 50 38751 38755
    • (2010) J Biol Chem , vol.285 , Issue.50 , pp. 38751-38755
    • Chang, S.H.1    Chung, Y.2    Dong, C.3
  • 208
    • 10044281540 scopus 로고    scopus 로고
    • Mounting evidence for Vitamin D as an environmental factor affecting autoimmune disease prevalence
    • Cantorna M. T., Mahon B. D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood): 2004; 229 11 1136 1142
    • (2004) Exp Biol Med (Maywood) , vol.229 , Issue.11 , pp. 1136-1142
    • Cantorna, M.T.1    Mahon, B.D.2
  • 209
    • 84876928036 scopus 로고    scopus 로고
    • A Vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response
    • Ding N., Yu R. T., Subramaniam N., et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell: 2013; 153 3 601 613
    • (2013) Cell , vol.153 , Issue.3 , pp. 601-613
    • Ding, N.1    Yu, R.T.2    Subramaniam, N.3
  • 210
    • 84922707696 scopus 로고    scopus 로고
    • Vitamin D: A new player in non-alcoholic fatty liver disease?
    • Eliades M., Spyrou E. Vitamin D: A new player in non-alcoholic fatty liver disease? World J Gastroenterol: 2015; 21 6 1718 1727
    • (2015) World J Gastroenterol , vol.21 , Issue.6 , pp. 1718-1727
    • Eliades, M.1    Spyrou, E.2
  • 211
    • 0037364216 scopus 로고    scopus 로고
    • Impaired insulin secretory capacity in mice lacking a functional Vitamin D receptor
    • Zeitz U., Weber K., Soegiarto D. W., Wolf E., Balling R., Erben R. G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J: 2003; 17 3 509 511
    • (2003) FASEB J , vol.17 , Issue.3 , pp. 509-511
    • Zeitz, U.1    Weber, K.2    Soegiarto, D.W.3    Wolf, E.4    Balling, R.5    Erben, R.G.6
  • 212
    • 84881476917 scopus 로고    scopus 로고
    • No significant association between Vitamin D and nonalcoholic fatty liver disease in a Chinese population
    • Li L., Zhang L., Pan S., Wu X., Yin X. No significant association between vitamin D and nonalcoholic fatty liver disease in a Chinese population. Dig Dis Sci: 2013; 58 8 2376 2382
    • (2013) Dig Dis Sci , vol.58 , Issue.8 , pp. 2376-2382
    • Li, L.1    Zhang, L.2    Pan, S.3    Wu, X.4    Yin, X.5
  • 213
    • 84875506039 scopus 로고    scopus 로고
    • High serum Vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome
    • Rhee E-J, Kim M. K., Park S. E., et al. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr J: 2013; 60 6 743 752
    • (2013) Endocr J , vol.60 , Issue.6 , pp. 743-752
    • Rhee, E.-J.1    Kim, M.K.2    Park, S.E.3
  • 214
    • 84879735651 scopus 로고    scopus 로고
    • Meta-analysis: Vitamin D and non-alcoholic fatty liver disease
    • Eliades M., Spyrou E., Agrawal N., et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther: 2013; 38 3 246 254
    • (2013) Aliment Pharmacol Ther , vol.38 , Issue.3 , pp. 246-254
    • Eliades, M.1    Spyrou, E.2    Agrawal, N.3
  • 215
    • 84902545822 scopus 로고    scopus 로고
    • Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease
    • Dasarathy J., Periyalwar P., Allampati S., et al. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int: 2014; 34 6 e118 e127
    • (2014) Liver Int , vol.34 , Issue.6 , pp. e118-e127
    • Dasarathy, J.1    Periyalwar, P.2    Allampati, S.3
  • 216
    • 84896945009 scopus 로고    scopus 로고
    • Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease
    • Nobili V., Giorgio V., Liccardo D., et al. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol: 2014; 170 4 547 553
    • (2014) Eur J Endocrinol , vol.170 , Issue.4 , pp. 547-553
    • Nobili, V.1    Giorgio, V.2    Liccardo, D.3
  • 217
    • 84655169612 scopus 로고    scopus 로고
    • The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: The NHS and the HPFS
    • Vaidya A., Williams J. S., Forman J. P. The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: The NHS and the HPFS. Obesity (Silver Spring): 2012; 20 1 186 191
    • (2012) Obesity (Silver Spring) , vol.20 , Issue.1 , pp. 186-191
    • Vaidya, A.1    Williams, J.S.2    Forman, J.P.3
  • 221
    • 0023937933 scopus 로고
    • Phenobarbital induction of cytochrome P-450 b,e genes is dependent on protein synthesis
    • Chianale J., Mulholland L., Traber P. G., Gumucio J. J. Phenobarbital induction of cytochrome P-450 b,e genes is dependent on protein synthesis. Hepatology: 1988; 8 2 327 331
    • (1988) Hepatology , vol.8 , Issue.2 , pp. 327-331
    • Chianale, J.1    Mulholland, L.2    Traber, P.G.3    Gumucio, J.J.4
  • 222
    • 0035185021 scopus 로고    scopus 로고
    • The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression
    • Nakae J., Kitamura T., Silver D. L., Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest: 2001; 108 9 1359 1367
    • (2001) J Clin Invest , vol.108 , Issue.9 , pp. 1359-1367
    • Nakae, J.1    Kitamura, T.2    Silver, D.L.3    Accili, D.4
  • 223
    • 39749171761 scopus 로고    scopus 로고
    • Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response
    • Moreau A., Vilarem M. J., Maurel P., Pascussi J. M. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol Pharm: 2008; 5 1 35 41
    • (2008) Mol Pharm , vol.5 , Issue.1 , pp. 35-41
    • Moreau, A.1    Vilarem, M.J.2    Maurel, P.3    Pascussi, J.M.4
  • 225
    • 33744948052 scopus 로고    scopus 로고
    • A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway
    • Zhou J., Zhai Y., Mu Y., et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem: 2006; 281 21 15013 15020
    • (2006) J Biol Chem , vol.281 , Issue.21 , pp. 15013-15020
    • Zhou, J.1    Zhai, Y.2    Mu, Y.3
  • 226
    • 84877798556 scopus 로고    scopus 로고
    • PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice
    • He J., Gao J., Xu M., et al. PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes: 2013; 62 6 1876 1887
    • (2013) Diabetes , vol.62 , Issue.6 , pp. 1876-1887
    • He, J.1    Gao, J.2    Xu, M.3
  • 227
    • 41149102969 scopus 로고    scopus 로고
    • Regulatory cross-talk between drug metabolism and lipid homeostasis: Constitutive androstane receptor and pregnane X receptor increase Insig-1 expression
    • Roth A., Looser R., Kaufmann M., et al. Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol Pharmacol: 2008; 73 4 1282 1289
    • (2008) Mol Pharmacol , vol.73 , Issue.4 , pp. 1282-1289
    • Roth, A.1    Looser, R.2    Kaufmann, M.3
  • 229
    • 85047693782 scopus 로고    scopus 로고
    • Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia
    • Pascussi J. M., Robert A., Nguyen M., et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest: 2005; 115 1 177 186
    • (2005) J Clin Invest , vol.115 , Issue.1 , pp. 177-186
    • Pascussi, J.M.1    Robert, A.2    Nguyen, M.3
  • 230
    • 0021850197 scopus 로고
    • Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects
    • Lahtela J. T., Arranto A. J., Sotaniemi E. A. Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes: 1985; 34 9 911 916
    • (1985) Diabetes , vol.34 , Issue.9 , pp. 911-916
    • Lahtela, J.T.1    Arranto, A.J.2    Sotaniemi, E.A.3
  • 231
    • 84929155646 scopus 로고    scopus 로고
    • Targeting xenobiotic receptors PXR and CAR in human diseases
    • Banerjee M., Robbins D., Chen T. Targeting xenobiotic receptors PXR and CAR in human diseases. Drug Discov Today: 2015; 20 5 618 628
    • (2015) Drug Discov Today , vol.20 , Issue.5 , pp. 618-628
    • Banerjee, M.1    Robbins, D.2    Chen, T.3
  • 232
    • 84866738222 scopus 로고    scopus 로고
    • Targeting xenobiotic receptors PXR and CAR for metabolic diseases
    • Gao J., Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci: 2012; 33 10 552 558
    • (2012) Trends Pharmacol Sci , vol.33 , Issue.10 , pp. 552-558
    • Gao, J.1    Xie, W.2
  • 234
    • 68149159139 scopus 로고    scopus 로고
    • PXR and CAR in energy metabolism
    • Wada T., Gao J., Xie W. PXR and CAR in energy metabolism. Trends Endocrinol Metab: 2009; 20 6 273 279
    • (2009) Trends Endocrinol Metab , vol.20 , Issue.6 , pp. 273-279
    • Wada, T.1    Gao, J.2    Xie, W.3
  • 235
    • 84895801586 scopus 로고    scopus 로고
    • REV-ERB and ROR nuclear receptors as drug targets
    • Kojetin D. J., Burris T. P. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov: 2014; 13 3 197 216
    • (2014) Nat Rev Drug Discov , vol.13 , Issue.3 , pp. 197-216
    • Kojetin, D.J.1    Burris, T.P.2
  • 237
    • 84885112550 scopus 로고    scopus 로고
    • Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis
    • Vonghia L., Michielsen P., Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci: 2013; 14 10 19867 19890
    • (2013) Int J Mol Sci , vol.14 , Issue.10 , pp. 19867-19890
    • Vonghia, L.1    Michielsen, P.2    Francque, S.3
  • 238
    • 80053651902 scopus 로고    scopus 로고
    • Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease
    • Tang Y., Bian Z., Zhao L., et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol: 2011; 166 2 281 290
    • (2011) Clin Exp Immunol , vol.166 , Issue.2 , pp. 281-290
    • Tang, Y.1    Bian, Z.2    Zhao, L.3
  • 239
    • 84865461464 scopus 로고    scopus 로고
    • Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice
    • 3
    • Meng F., Wang K., Aoyama T., et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology: 2012; 143 3 765 76.e1, 3
    • (2012) Gastroenterology , vol.143 , Issue.3 , pp. 765-76e1
    • Meng, F.1    Wang, K.2    Aoyama, T.3
  • 240
    • 84946722042 scopus 로고    scopus 로고
    • IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression
    • Giles D. A., Moreno-Fernandez M. E., Divanovic S. IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets: 2015; 16 12 1315 1323
    • (2015) Curr Drug Targets , vol.16 , Issue.12 , pp. 1315-1323
    • Giles, D.A.1    Moreno-Fernandez, M.E.2    Divanovic, S.3
  • 241
    • 58149512325 scopus 로고    scopus 로고
    • Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women
    • Sumarac-Dumanovic M., Stevanovic D., Ljubic A., et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes: 2009; 33 1 151 156
    • (2009) Int J Obes , vol.33 , Issue.1 , pp. 151-156
    • Sumarac-Dumanovic, M.1    Stevanovic, D.2    Ljubic, A.3
  • 242
    • 84885112550 scopus 로고    scopus 로고
    • Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis
    • Vonghia L., Michielsen P., Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci: 2013; 14 10 19867 19890
    • (2013) Int J Mol Sci , vol.14 , Issue.10 , pp. 19867-19890
    • Vonghia, L.1    Michielsen, P.2    Francque, S.3
  • 243
    • 84865772592 scopus 로고    scopus 로고
    • Small molecule inhibitors of RORγt: Targeting Th17 cells and other applications
    • Huh J. R., Littman D. R. Small molecule inhibitors of RORγt: Targeting Th17 cells and other applications. Eur J Immunol: 2012; 42 9 2232 2237
    • (2012) Eur J Immunol , vol.42 , Issue.9 , pp. 2232-2237
    • Huh, J.R.1    Littman, D.R.2
  • 244
    • 77955362775 scopus 로고    scopus 로고
    • Chronic inflammation in obesity and the metabolic syndrome
    • Monteiro R., Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm: 2010; 2010
    • (2010) Mediators Inflamm , vol.2010
    • Monteiro, R.1    Azevedo, I.2
  • 245
    • 84906730677 scopus 로고    scopus 로고
    • Is serum Interleukin-17 associated with early atherosclerosis in obese patients?
    • Tarantino G., Costantini S., Finelli C., et al. Is serum Interleukin-17 associated with early atherosclerosis in obese patients? J Transl Med: 2014; 12 214
    • (2014) J Transl Med , vol.12 , pp. 214
    • Tarantino, G.1    Costantini, S.2    Finelli, C.3
  • 246
    • 77649138576 scopus 로고    scopus 로고
    • Circadian rhythms and metabolic syndrome: From experimental genetics to human disease
    • Maury E., Ramsey K. M., Bass J. Circadian rhythms and metabolic syndrome: From experimental genetics to human disease. Circ Res: 2010; 106 3 447 462
    • (2010) Circ Res , vol.106 , Issue.3 , pp. 447-462
    • Maury, E.1    Ramsey, K.M.2    Bass, J.3
  • 248
    • 77955980762 scopus 로고    scopus 로고
    • Chronotherapy and the molecular clock: Clinical implications in oncology
    • Innominato P. F., Lévi F. A., Bjarnason G. A. Chronotherapy and the molecular clock: Clinical implications in oncology. Adv Drug Deliv Rev: 2010; 62 9-10 979 1001
    • (2010) Adv Drug Deliv Rev , vol.62 , Issue.9-10 , pp. 979-1001
    • Innominato, P.F.1    Lévi, F.A.2    Bjarnason, G.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.